A Phase 3 interventional study of tocilizumab [RoActemra/Actemra] and methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 70 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-15.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 18th largest by enrollment, is one of 9 that started in 2009, is one of 47 in phase 3, and was the 32nd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 9 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 418 is above the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 32nd largest by enrollment of the 141 interventional ones that give a count, is one of 22 that started in 2009, is one of 85 in phase 3, and was the 50th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This single arm, open-label study will assess the safety and efficacy with regar d to reduction of signs and symptoms of treatment with tocilizumab in combinatio n with methotrexate, in patients with moderate to severe active rheumatoid arthr itis. Patients will receive tocilizumab 8mg/kg iv, every 4 weeks and methotrexat e 10-25mg weekly. The anticipated time on study treatment is 3-12 months, and th e target sample size is \<500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: tocilizumab [RoActemra/Actemra] · Drug: methotrexate
Drug page: Tocilizumab
8mg/kg iv, every 4 weeks
10-25mg oral or parenteral weekly.
Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 24
ACR50 is defined as 50 percent (%) improvement in: a) Swollen Joints Count (SJC) and Tender Joints Count (TJC) and b) Three of the following 5 assessments: 1. Participant's global assessment of pain by Visual Analog Scale (VAS) 2. Participant's global assessment of disease activity (VAS) 3. Investigator/Physician's global assessment of disease activity (VAS) 4. Participant's assessment of disability measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) 5. Acute phase reactant levels - Erythrocyte Sedimentation Rate or C-Reactive Protein (ESR or CRP)
Time frame: Week 24
Percentage of Participants With ACR20 and ACR70 Response at Week 24
ACR20 and ACR70 are defined as 20 and 70 percent improvement respectively in: a) SJC and TJC and b) Three of the following 5 assessments: 1. Participant's global assessment of pain by VAS 2. Participant's global assessment of disease activity (VAS) 3. Investigator/Physician's global assessment of disease activity (VAS) 4. Participant's assessment of disability measured by HAQ-DI 5. Acute phase reactant (ESR or CRP)
Time frame: Week 24
Time to Onset of ACR20, ACR50, and ACR70
ACR20, ACR50 and ACR70 are defined as 20, 50 and 70 percent improvement respectively in: a) SJC and TJC and b) Three of the following 5 assessments: 1. Participant's global assessment of pain by VAS 2. Participant's global assessment of disease activity (VAS) 3. Investigator/Physician's global assessment of disease activity (VAS) 4. Participant's assessment of disability measured by HAQ-DI 5. Acute phase reactant (ESR or CRP)
Time frame: Baseline and Week 24
Change From Baseline in Hemoglobin at Week 24
Time frame: Baseline and Week 24
SJC and TJC at Baseline and Week 24
The number of swollen joints (66 joint count) were scored as swollen=1 and not swollen=0, and the number of tender joints (68 joint count ) were scored as tender=1 and not tender=0, and counted. Scores ranged from 0 to 66 for swollen joint counts and from 0 to 68 for tender joint counts. A positive change from baseline represents an improvement (a reduction in the number of swollen or tender joints).
Time frame: Baseline and Week 24
Percent Change From Baseline in SJC and TJC at Week 24
The number of swollen joints (66 joint count) were scored as swollen=1 and not swollen=0, and the number of tender joints (68 joint count ) were scored as tender=1 and not tender=0, and counted. Scores ranged from 0 to 66 for swollen joint counts and from 0 to 68 for tender joint counts. A positive change from baseline represents an improvement (a reduction in the number of swollen or tender joints).
Time frame: Baseline and Week 24
Pain as Assessed by the Participant at Baseline and Week 24
The participants assessed their pain using a 0 to 100 millimeter (mm) VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". The participants marked the line corresponding to the level of their pain and the distance from the left edge was measured. A positive change from baseline represents an improvement.
Time frame: Baseline and Week 24
Percent Change From Baseline in Pain as Assessed by the Participant at Week 24
The participants assessed their pain using a 0 to 100 millimeter (mm) VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". The participants marked the line corresponding to the level of their pain and the distance from the left edge was measured. A positive change from baseline represents an improvement.
Time frame: Baseline and Week 24
Participant's Global Assessment of Disease Activity at Baseline and Week 24
The participant's global assessment of disease activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A positive change from baseline represents an improvement (reduced level of disease activity).
Time frame: Baseline and Week 24
Percent Change From Baseline in Participant's Global Assessment of Disease Activity at Week 24
The participant's global assessment of disease activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A positive change from baseline represents an improvement (reduced level of disease activity).
Time frame: Baseline and Week 24
Physician's Global Assessment of Disease Activity at Baseline and Week 24
The physician's global assessment of disease activity is assessed on a 0 to 100 mm VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). The physicians marked the line corresponding to their assessment and the distance from the left edge was measured. A positive change from baseline represents an improvement (reduced level of disease activity).
Time frame: Baseline and Week 24
Percent Change From Baseline in Physician's Global Assessment of Disease Activity at Week 24
The physician's global assessment of disease activity is assessed on a 0 to 100 mm VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). The physicians marked the line corresponding to their assessment and the distance from the left edge was measured. A positive change from baseline represents an improvement (reduced level of disease activity).
Time frame: Baseline and Week 24
HAQ-DI at Baseline and Week 24
HAQ-DI includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0 =without difficulties; 1= with some difficulties; 2=with great difficulties; and 3= unable to perform these actions at all. Minimum score was 0, maximum score was 3. A positive change from baseline represents an improvement (reduced level of impairment).
Time frame: Baseline and Week 24
Percent Change From Baseline in HAQ-DI at Week 24
HAQ-DI includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3. A positive change from baseline represents an improvement (reduced level of impairment).
Time frame: Baseline and Week 24
Area Under The Curve (AUC) of the ACR(n)
ACR-n was defined as the lowest of 3 values (the percent change in the swollen joint count, the percent change in the tender joint count, and the median of the other 5 measures in the ACR core data set which included Participant's global assessment of pain (VAS), Participant's global assessment of disease activity (VAS), Investigator/Physician's global assessment of disease activity (VAS), Participant's assessment of disability measured by the HAQ-DI Acute phase reactant levels - ESR or CRP). Therefore, a percentage value was assigned to each participant at each timepoint. AUC was calculated for each participant from baseline to Week 112. Mean and standard deviation values are are provided in percent\*years.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving ACR20 Response
ACR20 is defined as 20% improvement in: a) SJC and TJC and b) Three of the following 5 assessments: 1. Participant's global assessment of pain (VAS) 2. Participant's global assessment of disease activity (VAS) 3. Investigator/Physician's global assessment of disease activity (VAS) 4. Participant's assessment of disability measured by the HAQ-DI 5. Acute phase reactant levels - ESR or CRP
Time frame: Week 2
Odds Estimates for ACR Positive Response in Generalized Estimating Equation (GEE) Models
The probability of ACR positive response was determined using the GEE.
Time frame: Weeks 2, 4, 8, 12, 16, 20, 24
Change From Baseline in Disease Activity Score Based on 28 Joint Count (DAS28) at Week 24
DAS28 calculated from the number of SJC and TJC using the 28 joints count, the ESR (mm/hour) and participant's global assessment of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 (less than or equal to ) ≤3.2 = low disease activity, DAS28 (greater than) \>3.2 to 5.1 = moderate to high disease activity.
Time frame: Baseline and Week 24
Percentage of Participants With a Response by Categorical DAS28 Responses According to The European League Against Rheumatism (EULAR Response) at Week 24
DAS28- based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good response: change from baseline \>1.2 with DAS28 \< 3.2; moderate response: change from baseline \>1.2 with DAS28 \>3.2 to \<5.1 or change from baseline \>0.6 to \<1.2 with DAS28 \<5.1; No response: change from baseline \< 0.6 or change from baseline \>0.6 and \<1.2 with DAS28 \>5.1.
Time frame: Week 24
AUC of DAS28
The AUC was computed using the trapezoidal rule, considering baseline value as 0, through NCSS software. For each participant, AUC for DAS28 units was calculated. Each individual AUC DAS28 value was divided by 52 to have the conversion of AUC DAS28 in unit weeks to AUC DAS28 in unit years, as 1 week is approximately 1/52 years. The set of individual AUC DAS28 was computed as summary statistics.
Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24
Fatigue as Assessed Using the Functional Assessment of Chronic Illness Therapy (FACIT-Fatigue) Score at Week 24
FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflects an improvement in the participant's health status.
Time frame: Week 24
Percentage of Participants Achieving Remission (DAS28 Less Than [<] 2.6) at Week 24
DAS28 calculated from the SJC and TJC using the 28 joints count, the ESR (mm/hour) and participant's global assessment of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 (less than or equal to ) ≤3.2 = low disease activity, DAS28 (greater than) \>3.2 to 5.1 = moderate to high disease activity and DAS28\<2.6 = remission
Time frame: Week 24
Quality of Life (QoL) Assessed by Short-Form 36 (SF-36) at Week 24
SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. Total of 3 variables were analyzed (2 composite subscales and vitality score). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Time frame: Week 24
Mean Change in Rheumatoid Factor (RF) at Week 24 in Participants With Positive RF
Time frame: Baseline and Week 24
| Milestone | Tocilizumab |
|---|---|
| Started | 418 |
| Completed | 347 |
| Not completed | 71 |
| Withdrew: Adverse event | 19 |
| Withdrew: Other | 39 |
| Withdrew: Protocol violation | 3 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Death | 1 |
| Withdrew: Administrative reason | 3 |
| Withdrew: Lost to follow-up | 1 |
ACR50 is defined as 50 percent (%) improvement in: a) Swollen Joints Count (SJC) and Tender Joints Count (TJC) and b) Three of the following 5 assessments: 1. Participant's global assessment of pain by Visual Analog Scale (VAS) 2. Participant's global assessment of disease activity (VAS) 3. Investigator/Physician's global assessment of disease activity (VAS) 4. Participant's assessment of disability measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) 5. Acute phase reactant levels - Erythrocyte Sedimentation Rate or C-Reactive Protein (ESR or CRP)
| percentage of participants | Tocilizumab |
|---|---|
| Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 24 | 73.23 (68.78 to 77.67) |
ACR20 and ACR70 are defined as 20 and 70 percent improvement respectively in: a) SJC and TJC and b) Three of the following 5 assessments: 1. Participant's global assessment of pain by VAS 2. Participant's global assessment of disease activity (VAS) 3. Investigator/Physician's global assessment of disease activity (VAS) 4. Participant's assessment of disability measured by HAQ-DI 5. Acute phase reactant (ESR or CRP)
| percentage of participants | Tocilizumab |
|---|---|
| ACR 20 | 90.55 (87.61 to 93.49) |
| ACR 70 | 50.39 (45.37 to 55.41) |
ACR20, ACR50 and ACR70 are defined as 20, 50 and 70 percent improvement respectively in: a) SJC and TJC and b) Three of the following 5 assessments: 1. Participant's global assessment of pain by VAS 2. Participant's global assessment of disease activity (VAS) 3. Investigator/Physician's global assessment of disease activity (VAS) 4. Participant's assessment of disability measured by HAQ-DI 5. Acute phase reactant (ESR or CRP)
No measurements were reported for this outcome.
No measurements were reported for this outcome.
The number of swollen joints (66 joint count) were scored as swollen=1 and not swollen=0, and the number of tender joints (68 joint count ) were scored as tender=1 and not tender=0, and counted. Scores ranged from 0 to 66 for swollen joint counts and from 0 to 68 for tender joint counts. A positive change from baseline represents an improvement (a reduction in the number of swollen or tender joints).
| joints | Tocilizumab |
|---|---|
| TJC-Baseline | 25.06 ± 13.83 |
| TJC-Week 24 | 4.57 ± 7.57 |
| SJC-Baseline | 16.09 ± 8.69 |
| SJC-Week 24 | 2.56 ± 4.26 |
The number of swollen joints (66 joint count) were scored as swollen=1 and not swollen=0, and the number of tender joints (68 joint count ) were scored as tender=1 and not tender=0, and counted. Scores ranged from 0 to 66 for swollen joint counts and from 0 to 68 for tender joint counts. A positive change from baseline represents an improvement (a reduction in the number of swollen or tender joints).
| percent change | Tocilizumab |
|---|---|
| TJC | 81.2 ± 28.1 |
| SJC | 84.8 ± 22.5 |
The participants assessed their pain using a 0 to 100 millimeter (mm) VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". The participants marked the line corresponding to the level of their pain and the distance from the left edge was measured. A positive change from baseline represents an improvement.
| mm | Tocilizumab |
|---|---|
| Baseline (n=384) | 68.01 ± 20.39 |
| Week 24 (n=381) | 22.94 ± 22.53 |
The participants assessed their pain using a 0 to 100 millimeter (mm) VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". The participants marked the line corresponding to the level of their pain and the distance from the left edge was measured. A positive change from baseline represents an improvement.
| percent change | Tocilizumab |
|---|---|
| Percent Change From Baseline in Pain as Assessed by the Participant at Week 24 | 54.2 ± 177.0 |
The participant's global assessment of disease activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A positive change from baseline represents an improvement (reduced level of disease activity).
| mm | Tocilizumab |
|---|---|
| Baseline (n=384) | 69.46 ± 20.84 |
| Week 24 (n=381) | 23.60 ± 22.68 |
The participant's global assessment of disease activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A positive change from baseline represents an improvement (reduced level of disease activity).
| percent change | Tocilizumab |
|---|---|
| Percent Change From Baseline in Participant's Global Assessment of Disease Activity at Week 24 | 61.7 ± 43.1 |
The physician's global assessment of disease activity is assessed on a 0 to 100 mm VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). The physicians marked the line corresponding to their assessment and the distance from the left edge was measured. A positive change from baseline represents an improvement (reduced level of disease activity).
| mm | Tocilizumab |
|---|---|
| Baseline (n=384) | 67.32 ± 16.64 |
| Week 24 (n=381) | 17.92 ± 18.16 |
The physician's global assessment of disease activity is assessed on a 0 to 100 mm VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). The physicians marked the line corresponding to their assessment and the distance from the left edge was measured. A positive change from baseline represents an improvement (reduced level of disease activity).
| percent change | Tocilizumab |
|---|---|
| Percent Change From Baseline in Physician's Global Assessment of Disease Activity at Week 24 | 71.2 ± 38.7 |
HAQ-DI includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0 =without difficulties; 1= with some difficulties; 2=with great difficulties; and 3= unable to perform these actions at all. Minimum score was 0, maximum score was 3. A positive change from baseline represents an improvement (reduced level of impairment).
| units on a scale | Tocilizumab |
|---|---|
| Baseline (n=384) | 1.70 ± 0.63 |
| Week 24 (n=376) | 0.79 ± 0.68 |
HAQ-DI includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3. A positive change from baseline represents an improvement (reduced level of impairment).
| percent change | Tocilizumab |
|---|---|
| Percent Change From Baseline in HAQ-DI at Week 24 | 52.0 ± 49.3 |
ACR-n was defined as the lowest of 3 values (the percent change in the swollen joint count, the percent change in the tender joint count, and the median of the other 5 measures in the ACR core data set which included Participant's global assessment of pain (VAS), Participant's global assessment of disease activity (VAS), Investigator/Physician's global assessment of disease activity (VAS), Participant's assessment of disability measured by the HAQ-DI Acute phase reactant levels - ESR or CRP). Therefore, a percentage value was assigned to each participant at each timepoint. AUC was calculated for each participant from baseline to Week 112. Mean and standard deviation values are are provided in percent\*years.
| percent*years | Tocilizumab |
|---|---|
| Area Under The Curve (AUC) of the ACR(n) | 20.8 ± 9.4 |
ACR20 is defined as 20% improvement in: a) SJC and TJC and b) Three of the following 5 assessments: 1. Participant's global assessment of pain (VAS) 2. Participant's global assessment of disease activity (VAS) 3. Investigator/Physician's global assessment of disease activity (VAS) 4. Participant's assessment of disability measured by the HAQ-DI 5. Acute phase reactant levels - ESR or CRP
| percentage of participants | Tocilizumab |
|---|---|
| Percentage of Participants Achieving ACR20 Response | 40.10 (35.23 to 44.97) |
The probability of ACR positive response was determined using the GEE.
| odds | Tocilizumab |
|---|---|
| Week 2 Odds ACR50 | 0.10 (0.07 to 0.14) |
| Week 4 Odds ACR50 | 0.33 (0.27 to 0.42) |
| Week 8 Odds ACR50 | 0.87 (0.72 to 1.05) |
| Week 12 Odds ACR50 | 1.39 (1.14 to 1.69) |
| Week 16 Odds ACR50 | 1.55 (1.28 to 1.89) |
| Week 20 Odds ACR50 | 1.86 (1.52 to 2.27) |
| Week 24 Odds ACR50 | 2.39 (1.93 to 2.95) |
| Week 2 Odds ACR20 | 0.63 (0.51 to 0.76) |
| Week 4 Odds ACR20 | 1.50 (1.24 to 1.83) |
| Week 8 Odds ACR20 | 4.80 (3.73 to 6.19) |
| Week 12 Odds ACR20 | 4.80 (3.73 to 6.19) |
| Week 16 Odds ACR20 | 4.65 (3.61 to 5.97) |
| Week 20 Odds ACR20 | 6.46 (4.88 to 8.56) |
| Week 24 Odds ACR20 | 6.88 (5.16 to 9.18) |
| Week 4 Odds ACR70 | 0.08 (0.06 to 0.12) |
| Week 8 Odds ACR70 | 0.27 (0.21 to 0.34) |
| Week 12 Odds ACR70 | 0.41 (0.34 to 0.51) |
| Week 16 Odds ACR70 | 0.53 (0.44 to 0.65) |
| Week 20 Odds ACR70 | 0.75 (0.62 to 0.91) |
| Week 24 Odds ACR70 | 0.92 (0.76 to 1.12) |
DAS28 calculated from the number of SJC and TJC using the 28 joints count, the ESR (mm/hour) and participant's global assessment of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 (less than or equal to ) ≤3.2 = low disease activity, DAS28 (greater than) \>3.2 to 5.1 = moderate to high disease activity.
| score on a scale | Tocilizumab |
|---|---|
| Change From Baseline in Disease Activity Score Based on 28 Joint Count (DAS28) at Week 24 | 4.4 ± 1.6 |
DAS28- based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good response: change from baseline \>1.2 with DAS28 \< 3.2; moderate response: change from baseline \>1.2 with DAS28 \>3.2 to \<5.1 or change from baseline \>0.6 to \<1.2 with DAS28 \<5.1; No response: change from baseline \< 0.6 or change from baseline \>0.6 and \<1.2 with DAS28 \>5.1.
| Percentage of Participants | Tocilizumab |
|---|---|
| Good Response | 68.17 (63.60 to 72.74) |
| Moderate Response | 29.57 (25.10 to 34.05) |
| No Response | 2.26 (0.80 to 3.71) |
The AUC was computed using the trapezoidal rule, considering baseline value as 0, through NCSS software. For each participant, AUC for DAS28 units was calculated. Each individual AUC DAS28 value was divided by 52 to have the conversion of AUC DAS28 in unit weeks to AUC DAS28 in unit years, as 1 week is approximately 1/52 years. The set of individual AUC DAS28 was computed as summary statistics.
| scores on a scale * years | Tocilizumab |
|---|---|
| AUC of DAS28 | 11.8 ± 4.2 |
FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflects an improvement in the participant's health status.
| score on a scale | Tocilizumab |
|---|---|
| Fatigue as Assessed Using the Functional Assessment of Chronic Illness Therapy (FACIT-Fatigue) Score at Week 24 | 39.9 ± 9.4 |
DAS28 calculated from the SJC and TJC using the 28 joints count, the ESR (mm/hour) and participant's global assessment of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 (less than or equal to ) ≤3.2 = low disease activity, DAS28 (greater than) \>3.2 to 5.1 = moderate to high disease activity and DAS28\<2.6 = remission
| percentage of participants | Tocilizumab |
|---|---|
| Percentage of Participants Achieving Remission (DAS28 Less Than [<] 2.6) at Week 24 | 48.41 (43.57 to 53.25) |
SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. Total of 3 variables were analyzed (2 composite subscales and vitality score). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
| score on a scale | Tocilizumab |
|---|---|
| General Health | 42.5 ± 12.9 |
| Physical functioning | 63.0 ± 24.2 |
| Role limitations due to physical health | 64.0 ± 23.9 |
| Role limitations due to emotional problems | 66.0 ± 24.1 |
| Energy/fatigue | 48.9 ± 10.6 |
| Emotional well-being | 54.5 ± 10.3 |
| Social functioning | 38.2 ± 12.7 |
| Pain | 63.6 ± 24.8 |
No measurements were reported for this outcome.
Collected over Adverse events were recorded from the date of first dose of drug administration until the end of study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab | — | 30/418 (7.2%) | 324/418 (77.5%) |
| Event | Tocilizumab |
|---|---|
| PneumoniaInfections and infestations | 3/418 |
| CellulitisInfections and infestations | 3/418 |
| Leukopenia NOSBlood and lymphatic system disorders | 2/418 |
| HypersensitivityImmune system disorders | 1/418 |
| ConstipationGastrointestinal disorders | 1/418 |
| AnaemiaBlood and lymphatic system disorders | 1/418 |
| BradicardiaCardiac disorders | 1/418 |
| BronchitisInfections and infestations | 1/418 |
| Chronic gastrointestinal bleedingGastrointestinal disorders | 1/418 |
| GastritisGastrointestinal disorders | 1/418 |
| Event | Tocilizumab |
|---|---|
| HypercholesterolemiaMetabolism and nutrition disorders | 71/418 |
| Hepatic enzyme increasedInvestigations | 70/418 |
| HeadacheNervous system disorders | 41/418 |
| Urinary tract infectionInfections and infestations | 41/418 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 39/418 |
| HypertensionVascular disorders | 32/418 |
| InfluenzaInfections and infestations | 32/418 |
| PharyngitisInfections and infestations | 30/418 |
| Leukopenia NOSBlood and lymphatic system disorders | 25/418 |
| Back painMusculoskeletal and connective tissue disorders | 22/418 |
Intention to treat (ITT) population: All participants who received at least one dose of study drug and who had at least one effectiveness measurement performed after baseline.
| Age, Continuous(years) | Tocilizumab |
|---|---|
| Mean | 48.69 ± 12.36 |
| Sex: Female, Male(Participants) | Tocilizumab |
|---|---|
| Female | 371 |
| Male | 47 |
The record gives a start of Feb 2009, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2015, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methotrexate